Trial Profile
An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary)
- Indications Amyloidosis; Lymphoma; Multiple myeloma
- Focus Adverse reactions
- Sponsors Takeda; Takeda Oncology
- 19 Oct 2022 This trial has been completed in Greece, according to European Clinical Trials Database record.
- 26 Oct 2021 Planned End Date changed from 1 Oct 2021 to 31 Dec 2023.
- 26 Oct 2021 Planned primary completion date changed from 1 Oct 2021 to 31 Dec 2023.